| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 43 | 2025 | 913 | 6.420 |
Why?
|
| Neoplasms | 20 | 2025 | 447 | 6.300 |
Why?
|
| Mass Screening | 23 | 2026 | 670 | 4.640 |
Why?
|
| Registries | 12 | 2024 | 449 | 3.800 |
Why?
|
| Humans | 183 | 2026 | 16832 | 3.780 |
Why?
|
| Databases, Factual | 13 | 2024 | 294 | 3.580 |
Why?
|
| Mammography | 12 | 2025 | 141 | 3.110 |
Why?
|
| Female | 130 | 2026 | 12193 | 2.980 |
Why?
|
| Surgeons | 7 | 2022 | 13 | 2.960 |
Why?
|
| Early Detection of Cancer | 14 | 2026 | 553 | 2.550 |
Why?
|
| Workload | 5 | 2020 | 26 | 2.130 |
Why?
|
| Estrogen Replacement Therapy | 10 | 2013 | 91 | 2.120 |
Why?
|
| Risk Assessment | 22 | 2020 | 1047 | 2.100 |
Why?
|
| United States | 45 | 2025 | 3858 | 2.090 |
Why?
|
| Melanoma | 12 | 2021 | 35 | 1.960 |
Why?
|
| Colonic Neoplasms | 13 | 2025 | 162 | 1.880 |
Why?
|
| Middle Aged | 76 | 2026 | 7515 | 1.850 |
Why?
|
| Adult | 67 | 2026 | 7255 | 1.820 |
Why?
|
| Colectomy | 13 | 2020 | 31 | 1.820 |
Why?
|
| Preventive Health Services | 8 | 2025 | 142 | 1.810 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2026 | 130 | 1.780 |
Why?
|
| Skin Neoplasms | 11 | 2021 | 59 | 1.760 |
Why?
|
| Patient Navigation | 3 | 2025 | 20 | 1.750 |
Why?
|
| Genes, BRCA2 | 5 | 2019 | 8 | 1.650 |
Why?
|
| Genes, BRCA1 | 5 | 2019 | 9 | 1.650 |
Why?
|
| Infant Health | 2 | 2023 | 2 | 1.520 |
Why?
|
| Pregnancy, Unplanned | 2 | 2023 | 7 | 1.520 |
Why?
|
| Maternal Health | 2 | 2023 | 6 | 1.510 |
Why?
|
| Task Performance and Analysis | 4 | 2020 | 9 | 1.460 |
Why?
|
| Pathologists | 13 | 2021 | 15 | 1.420 |
Why?
|
| Encephalomyelitis | 3 | 2015 | 3 | 1.370 |
Why?
|
| Fatigue Syndrome, Chronic | 3 | 2015 | 4 | 1.370 |
Why?
|
| Myalgia | 3 | 2015 | 10 | 1.360 |
Why?
|
| Menopause | 6 | 2013 | 60 | 1.310 |
Why?
|
| Aged | 53 | 2026 | 5901 | 1.300 |
Why?
|
| Primary Health Care | 6 | 2026 | 693 | 1.280 |
Why?
|
| Colorectal Surgery | 2 | 2020 | 3 | 1.260 |
Why?
|
| Tamoxifen | 3 | 2019 | 52 | 1.250 |
Why?
|
| Data Accuracy | 3 | 2024 | 26 | 1.230 |
Why?
|
| Male | 54 | 2025 | 9556 | 1.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 53 | 1.180 |
Why?
|
| Hot Flashes | 5 | 2008 | 37 | 1.150 |
Why?
|
| Rectal Neoplasms | 6 | 2017 | 75 | 1.140 |
Why?
|
| Anxiety | 4 | 2026 | 154 | 1.130 |
Why?
|
| Lymph Node Excision | 6 | 2025 | 13 | 1.120 |
Why?
|
| Mutation | 5 | 2019 | 86 | 1.120 |
Why?
|
| Biopsy | 14 | 2018 | 74 | 1.120 |
Why?
|
| Genetic Counseling | 3 | 2019 | 26 | 1.060 |
Why?
|
| Evidence-Based Medicine | 8 | 2017 | 160 | 1.060 |
Why?
|
| Breast | 11 | 2017 | 66 | 1.040 |
Why?
|
| Referral and Consultation | 10 | 2026 | 147 | 1.000 |
Why?
|
| Clinical Competence | 16 | 2023 | 107 | 0.990 |
Why?
|
| Laparoscopy | 8 | 2019 | 45 | 0.990 |
Why?
|
| Genetic Testing | 2 | 2019 | 63 | 0.980 |
Why?
|
| Pathology, Clinical | 11 | 2018 | 12 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 222 | 0.940 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2024 | 9 | 0.930 |
Why?
|
| Intimate Partner Violence | 1 | 2026 | 11 | 0.930 |
Why?
|
| Colorectal Neoplasms | 9 | 2020 | 635 | 0.920 |
Why?
|
| Quality of Health Care | 3 | 2024 | 249 | 0.920 |
Why?
|
| Urinary Incontinence | 4 | 2018 | 7 | 0.860 |
Why?
|
| Pregnancy Outcome | 6 | 2023 | 160 | 0.860 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 160 | 0.860 |
Why?
|
| Fractures, Bone | 7 | 2013 | 92 | 0.850 |
Why?
|
| Risk Factors | 22 | 2022 | 3108 | 0.850 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2019 | 11 | 0.840 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2024 | 9 | 0.820 |
Why?
|
| Age Factors | 14 | 2019 | 814 | 0.820 |
Why?
|
| Medicine | 2 | 2023 | 15 | 0.810 |
Why?
|
| Primary Prevention | 3 | 2013 | 60 | 0.800 |
Why?
|
| Feces | 7 | 2024 | 90 | 0.770 |
Why?
|
| Follow-Up Studies | 11 | 2024 | 1058 | 0.760 |
Why?
|
| Decision Making | 4 | 2020 | 164 | 0.750 |
Why?
|
| Anxiety Disorders | 2 | 2020 | 96 | 0.750 |
Why?
|
| Time Factors | 14 | 2021 | 989 | 0.730 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 9 | 2017 | 30 | 0.710 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2024 | 319 | 0.710 |
Why?
|
| Microbiota | 6 | 2019 | 10 | 0.700 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2010 | 42 | 0.700 |
Why?
|
| Precision Medicine | 2 | 2019 | 28 | 0.690 |
Why?
|
| Prognosis | 11 | 2025 | 568 | 0.670 |
Why?
|
| Surveys and Questionnaires | 11 | 2024 | 1204 | 0.660 |
Why?
|
| Benchmarking | 1 | 2021 | 32 | 0.650 |
Why?
|
| Pregnancy Complications | 2 | 2022 | 202 | 0.650 |
Why?
|
| Prospective Studies | 10 | 2024 | 1186 | 0.650 |
Why?
|
| Neoplasm Staging | 11 | 2025 | 322 | 0.640 |
Why?
|
| Ileus | 1 | 2020 | 1 | 0.630 |
Why?
|
| Chronic Disease | 2 | 2013 | 382 | 0.620 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 87 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2012 | 317 | 0.620 |
Why?
|
| Medical Overuse | 3 | 2017 | 14 | 0.620 |
Why?
|
| Mobile Applications | 1 | 2020 | 13 | 0.610 |
Why?
|
| Diagnostic Errors | 8 | 2019 | 30 | 0.610 |
Why?
|
| Chlamydia Infections | 2 | 2021 | 24 | 0.600 |
Why?
|
| Gonorrhea | 2 | 2021 | 20 | 0.600 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2019 | 10 | 0.600 |
Why?
|
| Estrogens | 3 | 2004 | 55 | 0.600 |
Why?
|
| Health Equity | 1 | 2020 | 26 | 0.590 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 34 | 0.590 |
Why?
|
| Postprandial Period | 1 | 2019 | 6 | 0.580 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2017 | 42 | 0.580 |
Why?
|
| Birth Intervals | 4 | 2018 | 7 | 0.570 |
Why?
|
| Adolescent | 11 | 2026 | 3464 | 0.560 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2019 | 2 | 0.560 |
Why?
|
| Treatment Outcome | 13 | 2017 | 1098 | 0.560 |
Why?
|
| Pregnancy | 11 | 2023 | 1555 | 0.560 |
Why?
|
| Diet | 2 | 2019 | 349 | 0.550 |
Why?
|
| Patient Participation | 3 | 2015 | 120 | 0.550 |
Why?
|
| Models, Statistical | 2 | 2019 | 164 | 0.550 |
Why?
|
| Quality Improvement | 4 | 2025 | 184 | 0.540 |
Why?
|
| Quality Indicators, Health Care | 2 | 2024 | 126 | 0.540 |
Why?
|
| RNA, Ribosomal, 16S | 7 | 2020 | 10 | 0.530 |
Why?
|
| Attitude of Health Personnel | 7 | 2023 | 197 | 0.520 |
Why?
|
| Postmenopause | 7 | 2019 | 243 | 0.510 |
Why?
|
| Blood Glucose | 1 | 2019 | 315 | 0.500 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 5 | 0.500 |
Why?
|
| Hospitals | 3 | 2022 | 69 | 0.500 |
Why?
|
| Endometrial Neoplasms | 5 | 2019 | 37 | 0.490 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 1887 | 0.480 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 1233 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 290 | 0.480 |
Why?
|
| Syphilis | 1 | 2016 | 18 | 0.480 |
Why?
|
| Observational Studies as Topic | 4 | 2022 | 44 | 0.470 |
Why?
|
| Infant | 4 | 2023 | 1212 | 0.470 |
Why?
|
| Veterans | 1 | 2017 | 143 | 0.460 |
Why?
|
| Suicide | 1 | 2017 | 114 | 0.460 |
Why?
|
| Young Adult | 15 | 2026 | 2456 | 0.460 |
Why?
|
| Medical Errors | 1 | 2015 | 16 | 0.450 |
Why?
|
| Counseling | 2 | 2015 | 170 | 0.440 |
Why?
|
| Retrospective Studies | 11 | 2025 | 2463 | 0.440 |
Why?
|
| Bacteria | 4 | 2024 | 9 | 0.430 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 41 | 0.430 |
Why?
|
| Specimen Handling | 4 | 2019 | 23 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 311 | 0.430 |
Why?
|
| Observer Variation | 11 | 2018 | 34 | 0.420 |
Why?
|
| Spouse Abuse | 2 | 2004 | 8 | 0.420 |
Why?
|
| Child Abuse | 2 | 2013 | 44 | 0.410 |
Why?
|
| Behavior Therapy | 2 | 2013 | 121 | 0.400 |
Why?
|
| Community Health Planning | 1 | 2013 | 16 | 0.400 |
Why?
|
| Accreditation | 2 | 2024 | 6 | 0.400 |
Why?
|
| Women's Health | 4 | 2022 | 178 | 0.400 |
Why?
|
| Thromboembolism | 4 | 2013 | 32 | 0.400 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 114 | 0.380 |
Why?
|
| Credentialing | 1 | 2013 | 2 | 0.380 |
Why?
|
| Domestic Violence | 2 | 2012 | 8 | 0.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 56 | 0.370 |
Why?
|
| Microscopy | 3 | 2018 | 5 | 0.370 |
Why?
|
| Mammary Glands, Human | 3 | 2017 | 5 | 0.360 |
Why?
|
| Sexual Partners | 1 | 2012 | 34 | 0.360 |
Why?
|
| Complementary Therapies | 2 | 2015 | 39 | 0.350 |
Why?
|
| Skin | 4 | 2020 | 12 | 0.350 |
Why?
|
| Osteoporosis | 2 | 2010 | 73 | 0.340 |
Why?
|
| Quality of Life | 6 | 2018 | 477 | 0.340 |
Why?
|
| Oregon | 3 | 2026 | 168 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 352 | 0.340 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2008 | 3 | 0.330 |
Why?
|
| Amines | 2 | 2008 | 4 | 0.330 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2008 | 4 | 0.330 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 346 | 0.330 |
Why?
|
| Pandemics | 5 | 2024 | 289 | 0.330 |
Why?
|
| Infant, Newborn | 3 | 2022 | 828 | 0.330 |
Why?
|
| Bayes Theorem | 3 | 2016 | 75 | 0.320 |
Why?
|
| Anastomotic Leak | 2 | 2020 | 2 | 0.320 |
Why?
|
| Dysbiosis | 3 | 2019 | 3 | 0.320 |
Why?
|
| Elective Surgical Procedures | 2 | 2020 | 10 | 0.320 |
Why?
|
| Survival Rate | 7 | 2022 | 247 | 0.320 |
Why?
|
| Survival Analysis | 7 | 2023 | 191 | 0.310 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 52 | 0.310 |
Why?
|
| Norpregnenes | 1 | 2009 | 1 | 0.310 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2009 | 2 | 0.310 |
Why?
|
| Societies, Medical | 5 | 2025 | 67 | 0.310 |
Why?
|
| Speech Disorders | 2 | 2008 | 3 | 0.310 |
Why?
|
| Language Development Disorders | 2 | 2008 | 3 | 0.310 |
Why?
|
| Meta-Analysis as Topic | 2 | 2007 | 23 | 0.300 |
Why?
|
| Pilot Projects | 2 | 2020 | 210 | 0.300 |
Why?
|
| Quality Assurance, Health Care | 2 | 2024 | 117 | 0.280 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2008 | 1 | 0.280 |
Why?
|
| Neonatal Screening | 1 | 2008 | 12 | 0.280 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2008 | 7 | 0.280 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 33 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2019 | 23 | 0.270 |
Why?
|
| Child | 6 | 2022 | 2433 | 0.270 |
Why?
|
| Breast Density | 3 | 2016 | 24 | 0.260 |
Why?
|
| Mastectomy | 4 | 2021 | 34 | 0.260 |
Why?
|
| Metabolomics | 2 | 2018 | 9 | 0.260 |
Why?
|
| Defensive Medicine | 2 | 2018 | 2 | 0.260 |
Why?
|
| False Positive Reactions | 3 | 2016 | 25 | 0.260 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 15 | 0.260 |
Why?
|
| Models, Genetic | 1 | 2007 | 21 | 0.260 |
Why?
|
| Malpractice | 2 | 2018 | 11 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2007 | 55 | 0.250 |
Why?
|
| Aging | 1 | 2008 | 146 | 0.250 |
Why?
|
| Dyslipidemias | 1 | 2007 | 57 | 0.250 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 571 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2025 | 4 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 145 | 0.240 |
Why?
|
| Sensitivity and Specificity | 4 | 2021 | 291 | 0.230 |
Why?
|
| Advisory Committees | 3 | 2018 | 112 | 0.230 |
Why?
|
| Breast Diseases | 2 | 2017 | 11 | 0.220 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 53 | 0.220 |
Why?
|
| Child, Preschool | 3 | 2019 | 1430 | 0.220 |
Why?
|
| Machine Learning | 1 | 2025 | 60 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 3 | 2013 | 12 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2026 | 288 | 0.210 |
Why?
|
| Survivorship | 1 | 2024 | 13 | 0.210 |
Why?
|
| Cancer Care Facilities | 2 | 2024 | 5 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2023 | 34 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2026 | 141 | 0.210 |
Why?
|
| Elder Abuse | 1 | 2004 | 3 | 0.210 |
Why?
|
| Estradiol | 1 | 2004 | 20 | 0.210 |
Why?
|
| SEER Program | 1 | 2024 | 86 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2025 | 155 | 0.200 |
Why?
|
| Feasibility Studies | 3 | 2021 | 108 | 0.200 |
Why?
|
| Postoperative Complications | 3 | 2022 | 103 | 0.200 |
Why?
|
| Minnesota | 3 | 2020 | 51 | 0.200 |
Why?
|
| Logistic Models | 8 | 2018 | 796 | 0.200 |
Why?
|
| Premature Birth | 2 | 2022 | 133 | 0.200 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 262 | 0.200 |
Why?
|
| Appendiceal Neoplasms | 1 | 2023 | 1 | 0.200 |
Why?
|
| Anus Neoplasms | 1 | 2023 | 28 | 0.190 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 19 | 0.190 |
Why?
|
| Family Health | 1 | 2023 | 40 | 0.190 |
Why?
|
| Intraoperative Care | 2 | 2021 | 2 | 0.190 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 653 | 0.190 |
Why?
|
| Information Dissemination | 1 | 2023 | 43 | 0.190 |
Why?
|
| Genome, Bacterial | 2 | 2020 | 2 | 0.190 |
Why?
|
| Multilocus Sequence Typing | 2 | 2020 | 2 | 0.190 |
Why?
|
| Infant, Low Birth Weight | 1 | 2022 | 30 | 0.190 |
Why?
|
| Lost to Follow-Up | 1 | 2022 | 2 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2024 | 114 | 0.190 |
Why?
|
| DNA, Bacterial | 2 | 2019 | 10 | 0.190 |
Why?
|
| Health Status | 1 | 2024 | 256 | 0.180 |
Why?
|
| Violence | 1 | 2022 | 32 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 28 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 107 | 0.180 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 27 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 60 | 0.180 |
Why?
|
| Bile Ducts | 1 | 2021 | 4 | 0.180 |
Why?
|
| Pancreatectomy | 1 | 2021 | 2 | 0.180 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2021 | 2 | 0.180 |
Why?
|
| Hydrogen Sulfide | 2 | 2018 | 2 | 0.170 |
Why?
|
| Whole Genome Sequencing | 2 | 2020 | 11 | 0.170 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 28 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2019 | 2396 | 0.170 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2018 | 4 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 23 | 0.160 |
Why?
|
| Uterus | 2 | 2019 | 2 | 0.160 |
Why?
|
| Clostridium Infections | 2 | 2018 | 13 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 21 | 0.160 |
Why?
|
| Reference Standards | 2 | 2017 | 14 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 14 | 0.160 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 8 | 0.160 |
Why?
|
| Molecular Epidemiology | 2 | 2017 | 33 | 0.160 |
Why?
|
| Anti-Anxiety Agents | 1 | 2020 | 5 | 0.160 |
Why?
|
| Overweight | 1 | 2022 | 262 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2020 | 1 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2020 | 2 | 0.160 |
Why?
|
| Ergonomics | 1 | 2020 | 1 | 0.160 |
Why?
|
| Nipples | 1 | 2020 | 2 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 97 | 0.160 |
Why?
|
| Posture | 1 | 2020 | 4 | 0.160 |
Why?
|
| United States National Aeronautics and Space Administration | 1 | 2019 | 2 | 0.150 |
Why?
|
| Education | 1 | 2020 | 14 | 0.150 |
Why?
|
| Occupational Health | 1 | 2020 | 15 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 23 | 0.150 |
Why?
|
| Asymptomatic Diseases | 2 | 2021 | 23 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 1 | 0.150 |
Why?
|
| Risk | 2 | 2016 | 453 | 0.150 |
Why?
|
| Patient Safety | 2 | 2017 | 37 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 17 | 0.150 |
Why?
|
| Women's Health Services | 1 | 2019 | 12 | 0.150 |
Why?
|
| Anal Canal | 1 | 2019 | 9 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2019 | 33 | 0.150 |
Why?
|
| Obesity | 2 | 2022 | 811 | 0.150 |
Why?
|
| Clostridiaceae | 1 | 2019 | 1 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 1 | 0.150 |
Why?
|
| Arthritis | 1 | 2019 | 5 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 17 | 0.140 |
Why?
|
| Occult Blood | 1 | 2020 | 161 | 0.140 |
Why?
|
| Incidence | 3 | 2019 | 1229 | 0.140 |
Why?
|
| False Negative Reactions | 2 | 2016 | 11 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 6 | 0.140 |
Why?
|
| Amino Acids | 1 | 2018 | 5 | 0.140 |
Why?
|
| Diarrhea | 1 | 2018 | 10 | 0.140 |
Why?
|
| Metabolome | 1 | 2018 | 3 | 0.140 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 520 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2018 | 73 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 702 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 5 | 0.140 |
Why?
|
| Proportional Hazards Models | 5 | 2012 | 657 | 0.140 |
Why?
|
| Professional Competence | 1 | 2018 | 15 | 0.140 |
Why?
|
| Job Satisfaction | 1 | 2018 | 19 | 0.140 |
Why?
|
| Models, Biological | 1 | 2018 | 26 | 0.140 |
Why?
|
| Age Distribution | 2 | 2015 | 221 | 0.130 |
Why?
|
| Perception | 2 | 2015 | 53 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 353 | 0.130 |
Why?
|
| Physicians | 2 | 2015 | 114 | 0.130 |
Why?
|
| Patient Selection | 2 | 2011 | 175 | 0.130 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 1 | 0.130 |
Why?
|
| Standard of Care | 1 | 2017 | 3 | 0.130 |
Why?
|
| Staphylococcal Protein A | 1 | 2017 | 1 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 5 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 489 | 0.130 |
Why?
|
| Bacteremia | 1 | 2017 | 11 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2017 | 2 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 213 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 69 | 0.130 |
Why?
|
| Sarcoma | 1 | 2017 | 2 | 0.130 |
Why?
|
| Groin | 1 | 2017 | 3 | 0.130 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 36 | 0.130 |
Why?
|
| Skin Aging | 1 | 2016 | 1 | 0.130 |
Why?
|
| Endometrial Hyperplasia | 1 | 2016 | 1 | 0.130 |
Why?
|
| Consensus | 4 | 2018 | 40 | 0.120 |
Why?
|
| Colonoscopy | 4 | 2016 | 261 | 0.120 |
Why?
|
| Adenomatous Polyps | 1 | 2016 | 16 | 0.120 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 7 | 0.120 |
Why?
|
| Colonic Polyps | 1 | 2016 | 35 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2016 | 3 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 30 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 45 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2016 | 38 | 0.120 |
Why?
|
| Ultrasonography, Mammary | 1 | 2016 | 4 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 6 | 0.120 |
Why?
|
| Health Care Costs | 2 | 2009 | 192 | 0.120 |
Why?
|
| Dermatology | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pathology | 1 | 2015 | 4 | 0.120 |
Why?
|
| Certification | 1 | 2015 | 3 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2019 | 995 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 65 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2019 | 925 | 0.110 |
Why?
|
| Poly I-C | 1 | 2015 | 1 | 0.110 |
Why?
|
| Poly U | 1 | 2015 | 1 | 0.110 |
Why?
|
| Intention | 1 | 2015 | 28 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 2 | 0.110 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2014 | 2 | 0.110 |
Why?
|
| Axilla | 3 | 2021 | 3 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 12 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2015 | 35 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2015 | 71 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2014 | 66 | 0.110 |
Why?
|
| Policy Making | 1 | 2014 | 14 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2015 | 92 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2016 | 136 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 43 | 0.110 |
Why?
|
| Maternal Age | 3 | 2018 | 73 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 98 | 0.100 |
Why?
|
| Bone Density | 3 | 2005 | 93 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2013 | 79 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2015 | 167 | 0.100 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2020 | 45 | 0.100 |
Why?
|
| Cataract | 1 | 2013 | 9 | 0.100 |
Why?
|
| House Calls | 1 | 2013 | 9 | 0.100 |
Why?
|
| Medical Audit | 1 | 2013 | 31 | 0.090 |
Why?
|
| Gallbladder Diseases | 1 | 2012 | 2 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 187 | 0.090 |
Why?
|
| Menopause, Premature | 1 | 2012 | 3 | 0.090 |
Why?
|
| Carpal Bones | 1 | 2012 | 3 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 7 | 0.090 |
Why?
|
| Phylogeny | 3 | 2017 | 18 | 0.090 |
Why?
|
| Reproductive History | 1 | 2012 | 13 | 0.090 |
Why?
|
| Child Health Services | 1 | 2013 | 104 | 0.090 |
Why?
|
| Mice | 2 | 2023 | 59 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 11 | 0.080 |
Why?
|
| Weight Gain | 2 | 2022 | 167 | 0.080 |
Why?
|
| Animals | 2 | 2023 | 237 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2013 | 235 | 0.080 |
Why?
|
| Melanocytes | 2 | 2021 | 2 | 0.080 |
Why?
|
| Breast Self-Examination | 1 | 2009 | 4 | 0.080 |
Why?
|
| Palpation | 1 | 2009 | 9 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 325 | 0.080 |
Why?
|
| Depression | 1 | 2014 | 479 | 0.070 |
Why?
|
| Models, Organizational | 1 | 2009 | 50 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2009 | 84 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 39 | 0.070 |
Why?
|
| Vagina | 2 | 2019 | 2 | 0.070 |
Why?
|
| Language Disorders | 1 | 2008 | 3 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2008 | 1 | 0.070 |
Why?
|
| Comorbidity | 2 | 2017 | 516 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 53 | 0.070 |
Why?
|
| Random Allocation | 2 | 2018 | 32 | 0.070 |
Why?
|
| Penetrance | 1 | 2007 | 2 | 0.060 |
Why?
|
| Stroke | 1 | 2009 | 297 | 0.060 |
Why?
|
| Data Collection | 2 | 2022 | 223 | 0.060 |
Why?
|
| Rectum | 1 | 2006 | 11 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2006 | 2 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 2 | 0.060 |
Why?
|
| Trifolium | 1 | 2006 | 2 | 0.060 |
Why?
|
| Soybeans | 1 | 2006 | 4 | 0.060 |
Why?
|
| Clonidine | 1 | 2006 | 3 | 0.060 |
Why?
|
| Isoflavones | 1 | 2006 | 14 | 0.060 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2006 | 3 | 0.060 |
Why?
|
| Urologic Neoplasms | 1 | 2006 | 7 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2006 | 14 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2026 | 36 | 0.060 |
Why?
|
| Language Therapy | 1 | 2006 | 1 | 0.060 |
Why?
|
| Speech Therapy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2026 | 47 | 0.060 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 1 | 0.060 |
Why?
|
| Workflow | 2 | 2020 | 11 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2005 | 30 | 0.060 |
Why?
|
| User-Computer Interface | 2 | 2016 | 21 | 0.060 |
Why?
|
| Minority Groups | 1 | 2006 | 99 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 140 | 0.050 |
Why?
|
| Metagenome | 1 | 2024 | 1 | 0.050 |
Why?
|
| Climacteric | 1 | 2004 | 2 | 0.050 |
Why?
|
| Germ Cells | 1 | 2024 | 2 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 5 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 7 | 0.050 |
Why?
|
| Health Services | 1 | 2004 | 100 | 0.050 |
Why?
|
| Heterografts | 1 | 2023 | 2 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 17 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2023 | 23 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 169 | 0.050 |
Why?
|
| Knowledge | 1 | 2023 | 3 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 89 | 0.050 |
Why?
|
| Cholecystitis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 3 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2002 | 13 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 4 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2002 | 11 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 15 | 0.040 |
Why?
|
| Bile | 1 | 2021 | 5 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2021 | 3 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 18 | 0.040 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2020 | 1 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 112 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2020 | 2 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2020 | 2 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 2020 | 4 | 0.040 |
Why?
|
| Surgical Oncology | 1 | 2020 | 1 | 0.040 |
Why?
|
| Mental Fatigue | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neck | 1 | 2020 | 1 | 0.040 |
Why?
|
| Torso | 1 | 2020 | 2 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2020 | 3 | 0.040 |
Why?
|
| Operative Time | 1 | 2020 | 4 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2020 | 5 | 0.040 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 6 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2020 | 100 | 0.040 |
Why?
|
| Porphyromonas | 1 | 2019 | 1 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 35 | 0.040 |
Why?
|
| Endometrium | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2020 | 15 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 2 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 569 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 24 | 0.040 |
Why?
|
| Dementia | 1 | 2002 | 137 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 30 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2019 | 20 | 0.040 |
Why?
|
| Dermatologists | 1 | 2019 | 2 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 105 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 198 | 0.040 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 26 | 0.040 |
Why?
|
| Bacteroides | 1 | 2018 | 2 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2018 | 1 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2018 | 1 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 2018 | 11 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 36 | 0.040 |
Why?
|
| Parity | 1 | 2018 | 53 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 376 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2018 | 55 | 0.030 |
Why?
|
| Hip Fractures | 2 | 2012 | 72 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 67 | 0.030 |
Why?
|
| Clostridium perfringens | 1 | 2018 | 1 | 0.030 |
Why?
|
| Fusobacterium nucleatum | 1 | 2018 | 1 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 67 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 15 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 49 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2018 | 30 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2018 | 10 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 513 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 1 | 0.030 |
Why?
|
| Freezing | 1 | 2017 | 1 | 0.030 |
Why?
|
| Bangladesh | 1 | 2017 | 3 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 20 | 0.030 |
Why?
|
| Documentation | 1 | 2017 | 37 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 1 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Ovary | 1 | 2016 | 5 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 88 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2016 | 1 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 190 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 78 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 25 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 560 | 0.030 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2016 | 2 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 10 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 24 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 68 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 54 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 21 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2014 | 1 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 34 | 0.030 |
Why?
|
| Gene Library | 1 | 2014 | 4 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 10 | 0.030 |
Why?
|
| Software | 1 | 2014 | 18 | 0.030 |
Why?
|
| New Hampshire | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vermont | 1 | 2014 | 1 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 4 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 410 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 60 | 0.030 |
Why?
|
| Premenopause | 1 | 2014 | 20 | 0.030 |
Why?
|
| Colloids | 1 | 2013 | 1 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2013 | 3 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 13 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2013 | 16 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2014 | 201 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 129 | 0.020 |
Why?
|
| General Surgery | 1 | 2011 | 2 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 15 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 319 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 19 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 110 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 207 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2009 | 7 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2009 | 11 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 25 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 25 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 3 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 45 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 68 | 0.020 |
Why?
|
| United States Public Health Service | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 90 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 3 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 2006 | 1 | 0.010 |
Why?
|
| American Cancer Society | 1 | 2006 | 12 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 785 | 0.010 |
Why?
|
| Calcaneus | 1 | 2005 | 5 | 0.010 |
Why?
|
| Femur Neck | 1 | 2005 | 6 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 32 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 54 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 229 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 25 | 0.010 |
Why?
|
| Analgesics | 1 | 2002 | 25 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 103 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 261 | 0.010 |
Why?
|
| Length of Stay | 1 | 2002 | 169 | 0.010 |
Why?
|